Table 3.

SNPs associated with clinical outcome in patients receiving fluoropyrimidine -based adjuvant chemotherapy

SNP	Model	Training Set				Replication Set			Pooled Analysis
		HR(95%CI)	P value*	Log rank p	Genotype Distribution MM/MV/VV#	HR(95%CI)	P value*	Genotype Distribution MM/MV/VV	HR(95%CI)	P value*	Genotype Distribution MM/MV/VV	Cochran’s Q-test P value†
Recurrence:
Stage II
rs10211390	recessive	2.79(1.16–6.71)	0.02	0.03	39/52/24	1.93(0.73–5.13)	0.18	26/18/8	2.37(1.23–4.54)	0.01	65/70/32	0.58
rs2421099	dominant	2.44(1.08–5.51)	0.03	0.16	86/25/4	0.50(0.24–1.08)	0.08	38/14/0	1.04(0.60–1.80)	0.90	124/39/4	0.005
rs7849	dominant	2.39(1.04–5.52)	0.04	0.03	80/28/7	3.70(1.42–9.64)	0.007	36/11/5	2.89(1.54–5.41)	0.001	116/39/12	0.50
rs16983007	dominant	2.81(1.02–7.70)	0.04	0.03	102/3/10	1.23(0.28–5.34)	0.78	44/6/2	2.16(0.94–4.97)	0.07	146/9/12	0.36
Stage III
rs10211390	recessive	2.70(1.12–6.50)	0.03	0.007	63/84/22	1.60(0.77–3.35)	0.21	45/47/14	1.98(1.13–3.49)	0.02	108/131/36	0.37
rs6124509	dominant	0.38(016–0.91)	0.03	0.04	118/47/4	1.00(0.59–1.70)	1.00	71/32/3	0.77(0.49–1.21)	0.26	189/79/7	0.06
rs11195893	dominant	0.26(0.08–0.91)	0.04	0.61	139/30/1	0.83(0.42–1.61)	0.58	90/15/1	0.63(0.35–1.14)	0.13	229/45/2	0.10
Survival:
Stage II
rs6590611	additive	2.92(1.22–7.02)	0.02	0.05	54/52/9	1.46(0.63–3.35)	0.38	28/22/2	2.03(1.11–3.72)	0.02	82/74/11	0.26
Stage III
rs9942838	recessive	3.23(1.17–8.92)	0.02	0.17	44/88/38	1.27(0.57–2.83)	0.55	27/47/32	1.82(0.97–3.41)	0.06	71/135/70	0.16

^*Adjusted by age, gender, ethnicity, smoking status and histologic grade

^†Cochran’s Q statistic to test for heterogeneity between studies

^#M: major allele, V: variant allele